Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 05 2021
01 05 2021
Historique:
received:
28
09
2020
revised:
25
11
2020
accepted:
11
12
2020
pubmed:
11
2
2021
medline:
17
3
2022
entrez:
10
2
2021
Statut:
ppublish
Résumé
Cancer clinical trials often accrue slowly or miss enrollment targets. Strict eligibility criteria are a major reason. Restrictive criteria also limit opportunities for patient participation while compromising external validity of trial results. We examined the impact of broadening select eligibility criteria on characteristics and number of patients eligible for trials, using recommendations of the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research. A retrospective, observational analysis used electronic health record data from ASCO's CancerLinQ Discovery database. Study cohort included patients with advanced non-small cell lung cancer treated from 2011 to 2018. Patients were grouped by traditional criteria [no brain metastases, no other malignancies, and creatinine clearance (CrCl) ≥ 60 mL/minute] and broadened criteria (including brain metastases, other malignancies, and CrCl ≥ 30 mL/minute). The analysis cohort included 10,500 patients. Median age was 68 years, and 73% of patients were White. Most patients had stage IV disease (65%). A total of 5,005 patients (48%) would be excluded from trial participation using the traditional criteria. The broadened criteria, however, would allow 98% of patients (10,346) to be potential participants. Examination of patients included by traditional criteria (5,495) versus those added (4,851) by broadened criteria showed that the number of women, patients aged 75+ years, and those with stage IV cancer was significantly greater using broadened criteria. This analysis of real-world data demonstrated that broadening three common eligibility criteria has the potential to double the eligible patient population and include trial participants who are more representative of those encountered in practice.
Identifiants
pubmed: 33563634
pii: 1078-0432.CCR-20-3857
doi: 10.1158/1078-0432.CCR-20-3857
doi:
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
2430-2434Commentaires et corrections
Type : CommentIn
Informations de copyright
©2021 American Association for Cancer Research.
Références
Cheng S, Dietrich M, Finnigan S, Sandler A, Crites J, Ferranti L, et al. A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies. J Clin Oncol. 2009;27:325s.
A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. 2010;143.
Cheng SK, Dietrich MS, Dilts DM. A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of Cancer Therapy Evaluation Program (NCI-CTEP) sponsored studies. Clin Cancer Res. 2010;16:5557–63.
Schroen AT, Petroni GR, Wang H, Thielen MJ, Gray R, Benedetti J, et al. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clin Cancer Res. 2012;18:256–62.
Korn EL, Freidlin B, Mooney M, Abrams JS. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007. J Clin Oncol. 2010;28:5197–201.
Bennette CS, Ramsey SD, McDermott CL, Carlson JJ, Basu A, Veenstra DL. Predicting low accrual in the National Cancer Institute’s Cooperative Group clinical trials. J Natl Cancer Inst. 2016;108:djv324.
Demmy TL, Yasko JM, Collyar DE, Katz ML, Krasnov CL, Borwhat MJ, et al. Managing accrual in Cooperative Group clinical trials. J Clin Oncol. 2004;22:2997–3002.
Massett HA, Mishkin G, Rubinstein L, Ivy SP, Denicoff A, Godwin E, et al. Challenges facing early phase trials sponsored by the National Cancer Institute: an analysis of corrective action plans to improve accrual. Clin Cancer Res. 2016;22:5408–16.
Malik L, Lu D. Eligibility criteria for phase I clinical trials: tight vs loose?. Cancer Chemother Pharmacol. 2019;83:999–1002.
Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. JNCI. 2019;111:245–55.
Donia M, Ellebaek E, Øllegaard TH, Duval L, Aaby JB, Hoejberg L, et al. The real-world impact of modern treatments on the survival of patients with metastatic melanoma. Eur J Cancer. 2019;108:25–32.
Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, et al. Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement. J Clin Oncol. 2017;35:3737–44.
Lin NU, Prowell T, Tan AR, Kozak M, Rosen O, Amiri-Kordestani L, et al. Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Brain Metastases Working Group. J Clin Oncol. 2017;35:3760–73.
Lichtman SM, Harvey RD, Damiette Smit M-A, Rahman A, Thompson MA, Roach N, et al. Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group. J Clin Oncol. 2017;35:3753–9.
Uldrick TS, Ison G, Rudek MA, Noy A, Schwartz K, Bruinooge S, et al. Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology–Friends of Cancer Research HIV Working Group. J Clin Oncol. 2017;35:3774–80.
Gore L, Ivy SP, Balis FM, Rubin E, Thornton K, Donoghue M, et al. Modernizing clinical trial eligibility: recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Minimum Age Working Group. J Clin Oncol. 2017;35:3781–7.
LLC: Lung Data (2011–2018), November 30, 2018 dataset.
.
Schilsky RL, Michels DL, Kearbey AH, Yu PP, Hudis CA. Building a rapid learning health care system for oncology: the regulatory framework of CancerLinQ. J Clin Oncol. 2014;32:2373–9.
Shah A, Stewart AK, Kolacevski A, Michels D, Miller R. Building a rapid learning health care system for oncology: why CancerLinQ collects identifiable health information to achieve its vision. J Clin Oncol. 2016;34:756–63.
Jin S, Pazdur R, Sridhara R. Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015. J Clin Oncol. 2017;35:3745–52.
Coresh J, Stevens LA. Kidney function estimating equations: where do we stand?. Curr Opin Nephrol Hypertens. 2006;15:276–84.
Stevens LA, Li S, Kurella Tamura M, Chen S-C, Vassalotti JA, Norris KC, et al. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011;57:S9–S16.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.
Kawachi H, Fujimoto D, Morimoto T, Ito M, Teraoka S, Sato Y, et al. Clinical characteristics and prognosis of patients with advanced non–small-cell lung cancer who are ineligible for clinical trials. Clin Lung Cancer. 2018;19:721–4.